

Accepted Manuscript

The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen

Hamish Innes, Stephen T. Barclay, Peter C. Hayes, Andrew Fraser, John F. Dillon, Adrian Stanley, Andy Bathgate, Scott A McDonald, David Goldberg, Heather Valerio, Ray Fox, Nick Kennedy, Pete Bramley, Sharon J. Hutchinson

PII: S0168-8278(17)32429-7
DOI: <https://doi.org/10.1016/j.jhep.2017.10.033>
Reference: JHEPAT 6748

To appear in: *Journal of Hepatology*

Received Date: 15 May 2017
Revised Date: 18 October 2017
Accepted Date: 30 October 2017

Please cite this article as: Innes, H., Barclay, S.T., Hayes, P.C., Fraser, A., Dillon, J.F., Stanley, A., Bathgate, A., McDonald, S.A., Goldberg, D., Valerio, H., Fox, R., Kennedy, N., Bramley, P., Hutchinson, S.J., The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen, *Journal of Hepatology* (2017), doi: <https://doi.org/10.1016/j.jhep.2017.10.033>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



TITLE: The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen

AUTHORS & AFFILIATIONS:

Hamish Innes ^{1,2}, Stephen T. Barclay ³, Peter C. Hayes ⁴, Andrew Fraser ⁵, John F. Dillon ⁶, Adrian Stanley ³, Andy Bathgate ⁴, Scott A McDonald ^{1,2}, David Goldberg ^{2,1}, Heather Valerio ^{1,2}, Ray Fox ⁷, Nick Kennedy ⁸, Pete Bramley ⁹, Sharon J. Hutchinson ^{1,2}

1. School of Health and Life Sciences, Glasgow Caledonian University
2. Health Protection Scotland, Glasgow, UK
3. Glasgow Royal Infirmary, Glasgow, UK
4. Royal Infirmary Edinburgh, Edinburgh, UK
5. Aberdeen Royal Infirmary, Aberdeen, UK
6. Ninewells Hospital and Medical School, Dundee, UK
7. The Brownlee Centre, Glasgow UK,
8. Monklands Hospital, Lanarkshire UK,
9. Stirling Royal Infirmary, Stirling, UK

WORD COUNT: 3,650 (including introduction, methods, results and discussion).

CONFLICTS OF INTEREST:

HI reports personal fees from Gilead Sciences, grants from Health Protection Scotland, outside the submitted work. DG reports personal fees from Gilead, personal fees from Merck, personal fees from Abbvie, outside the submitted work. JD reports grants and personal fees from Gilead, grants and personal fees from MSD, grants and personal fees from Abbvie, grants and personal fees from Janssen, outside the submitted work. PH reports personal fees from MSD, personal fees from Gilead, personal fees from Abbvie, personal fees from Janssen, personal fees from BMS, personal fees from Pfizer, grants and personal fees from Roche, during the conduct of the study. RF reports personal fees from Gilead, personal fees from Abbvie, personal fees from MSD, outside the submitted work. SB reports personal fees from Gilead, grants and personal fees from Abbvie, personal fees from MSD, personal fees from Janssen, outside the submitted work. SH reports grants from Health Protection Scotland, during the conduct of the study. AB reports personal fees from Abbvie, outside the submitted work. RF is an Advisory Board member for Abbvie, Gilead, MSD. All other authors have nothing to disclose.

ABBREVIATIONS (IN ORDER OF APPEARANCE):

HCV, Hepatitis C Virus; IFN, Interferon; HCC, Hepatocellular Carcinoma; CTP, Child Turcotte Pugh; DAA, Direct Acting Antiviral; SVR, Sustained Viral Response; SIMD Scottish Index of Multiple Deprivation; GGC Greater Glasgow and Clyde; HR Hazard Ratio; aHR Adjusted Hazard Ratio

AUTHOR CONTRIBUTIONS: SH, SB, HI and PH contributed to conception of the study and the analysis plan. HI carried out the statistical analysis. SH, SB AND HI drafted the manuscript. All authors contributed to the interpretation of results, acquisition of data and critical revision of the manuscript.

FUNDING: This work was supported by funding from Health Protection Scotland.

KEYWORDS: hepatocellular carcinoma; interferon-free therapy; direct acting antivirals, sustained viral response, cirrhosis

ABSTRACT

BACKGROUND: Previous studies have reported a high frequency of hepatocellular carcinoma (HCC) occurrence in patients with advanced liver disease, after receipt of interferon(IFN)-free therapy for hepatitis C virus (HCV) infection. Our objective was to verify and account for this phenomenon using data from the Scottish HCV Clinical Database.

METHODS: We identified HCC-naïve individuals with liver cirrhosis receiving a course of antiviral therapy in Scotland from 1997-2016 resulting in a SVR. Patients were followed-up from their treatment start date to the earliest of: date of death, date of HCC occurrence, or Jan 2017. We used Cox regression to compare the risk of HCC occurrence according to treatment regimen after adjusting for relevant co-factors (including: demographic factors; baseline liver disease stage; comorbidities/health behaviours, virology, and previous treatment experience). HCC occurrence was ascertained through the both the HCV clinical database and medical chart review. For our main analysis, treatment regimen was defined as IFN-free versus IFN-containing.

RESULTS: 857 patients met the study criteria, of whom 31.7% received an IFN-free regimen. Individuals receiving IFN-free therapy were more likely to be: older; of white ethnicity, Child-Turcotte-Pugh B/C vs. Child-Turcotte-Pugh A; thrombocytopenic; non-genotype 3; and treatment experienced. HCC occurrence was observed in 46 individuals during follow-up. In univariate analysis, IFN-free receipt was associated with a significantly increased risk of HCC (HR: 2.48; $P=0.021$). However after multivariate adjustment for baseline factors, no significant risk attributable to IFN-free therapy persisted (aHR: 1.15, $P=0.744$).

CONCLUSION: These findings suggest that the higher incidence of HCC following SVR with IFN-free therapy relates to baseline risk factors/patient selection, and not the use of IFN-free therapy per se.

LAY SUMMARY: We examined the risk of liver cancer among 857 patients with cirrhosis in Scotland who received hepatitis C antiviral therapy and achieved a cure. We compared the risk of first-time liver cancer in patients treated with the newest interferon-free regimens, to patients treated with interferon. After accounting for the different characteristics of these two treatment groups, we found no evidence that interferon-free therapy is associated with a higher risk of liver cancer.

INTRODUCTION

The arrival of interferon (IFN)-free direct acting antiviral (DAA) regimens from 2014-2015 has transformed the treatment of hepatitis C virus (HCV) infection. In addition to causing few adverse effects and being convenient to administer (i.e. with one tablet per day dosing for only 8-12 weeks), IFN-free therapy results in cure rates exceeding 90%, even in patients with advanced liver disease. [1,2] With IFN-based regimens, a cure is associated with a 81% (95% CI: 56-92), and 94% (95% CI: 81-98) reduction in the risk of hepatocellular carcinoma (HCC) and liver mortality, respectively for patients with advanced fibrosis [3]. The relatively recent introduction of IFN-free therapy however, means that we do not yet know what the analogous value of an IFN-free cure is – i.e. whether it is better, worse or equivalent to an IFN-based cure (although the assumption thus far, for instance in cost effectiveness modelling work[4], has been one of equivalence).

Recently, a number of European studies have described high rates of HCC occurrence and recurrence following receipt of IFN-free regimens.[5-8] Reig et al reported that of 58 patients from Spain with a complete radiological response to HCC, 16 (27.6%) developed HCC recurrence 5.7 months after receiving an IFN-free regimen. [5] Similarly, Conti et al reported that of 59 patients from Italy with a complete response to resection/ablation of HCC, 28.8% developed HCC recurrence 24 weeks after starting IFN-free treatment. [6] In terms of HCC occurrence, Conti et al report that 3.2% of 285 cirrhotic patients developed HCC for the first time by 24 weeks after starting IFN-free therapy in Italy. [6] Another study from Portugal noted a similar rate of HCC occurrence (7.4% with HCC at twelve months after starting an IFN-free regimen). [7] Prima facie, this level of HCC recurrence and occurrence is higher than expected. For instance, data from the STORM trial following individuals after successful response to surgical resection/local ablation of HCC, reported ~15-20% HCC recurrence at six months [9]. Meanwhile, HCC occurrence in cirrhotic patients attaining a hepatitis C cure through pegylated interferon and ribavirin has ranged from 1.0-1.4% per annum. [10,11]

Two theories have dominated the discussion of these findings thus far. Firstly, Reig et al and others have speculated that the rapid decline in hepatitis C viral load upon starting antiviral therapy, and the abrupt cessation of liver inflammation that results from this, may have the unintended consequence of adversely dampening cancer immune-surveillance activities that serve to identify and remove cancer-prone hepatocytes. Individuals receiving IFN-free therapy may be particularly prone to this theoretical mechanism for HCC because the transition to undetectable viral load is far more rapid with IFN-free therapies relative to IFN-containing regimens, and/or because IFN has anti-proliferative and immune-modulating properties that may offset any such immune surveillance down-regulation. [5]

Alternatively, others have suggested that the higher risk of HCC reflects a shift in the case mix of individuals attaining a HCV cure post-IFN-free availability. [12] That is to say, patients treated and achieving sustained viral response (SVR) with IFN-free therapy may on average, have a greater pre-

existing risk of HCC relative to those treated with IFN-containing regimens, making uncontrolled comparisons misleading.

Data reporting the risk of HCC by treatment regimen from large and representative cohorts of cured HCV patients are needed to answer this important question. Thus, we herein used the well-characterised Scottish Hepatitis C clinical database – a nationwide registry of HCV treatment patients - to identify cirrhotic patients attaining SVR in Scotland between 1997 and 2016. Our objective was to examine the incidence of de novo HCC occurrence according to the type of regimen received. In particular, we wanted to assess the credibility of the shifting case mix theory – that is whether differences in patient characteristics could account for the “higher” risk of HCC occurrence following receipt of IFN-free regimens versus IFN-containing regimens.

METHODS:

DATA SOURCE: CLINICAL DATABASE AND MEDICAL CHART REVIEW

We used data from the Scottish HCV clinical database, which consists of standalone Microsoft Access databases installed at 17/18 HCV treatment clinics across Scotland. Each database captures detailed clinical and epidemiological information on individuals who have attended an appointment for care/management of HCV infection [13,14]. An anonymised extract of each database is downloaded annually by Health Protection Scotland and assembled into several nationwide datasets (at the time of this analysis, the latest extracts were complete up to May 2016). Patients on the clinical database have provided informed “opt-out” consent for use of their data in administrative and research purposes.

In this study, key data from the clinical database were supplemented with a medical chart review carried out in February and March of 2017 by data entry staff and lead clinicians at participating clinics. This chart review entailed the retrieval and study of an individual’s medical records to obtain information on HCC occurrence, mortality events and relevant exposure variables, where that information was missing, or otherwise not available from the database at the time of the last download. The study protocol was approved by the Scottish HCV Clinical database monitoring committee.

INCLUSION/EXCLUSION CRITERIA:

This study included patients from the 12 Scottish HCV clinics, whose clinical database was complete at the time of the last download, and that were able to carry out the requisite medical chart review. Collectively, these 12 clinics account for circa 85% of all HCV treatment episodes occurring nationally in Scotland. We identified all individuals at these clinics who: (i) attained sustained viral response (SVR) between 1 Jan 1997 and 1 April 2016; and (ii) had received a diagnosis of liver cirrhosis prior to commencing therapy. We excluded patients with hepatitis B or HIV co-infection prior to treatment, or with HCC prior to starting treatment. An SVR was defined as testing viral RNA negative for a minimum of 12 or 24 weeks following completion of treatment, as per clinical guidelines. Up to 2014, the minimum time period required to establish SVR was exclusively 24 weeks (i.e. a SVR 24). From 2014, in keeping with changed clinical guidelines [15] reflecting strong concordance between SVR12 and SVR24 [16], SVR was defined as a negative test beyond 12 weeks post-treatment.

PRIMARY OUTCOME EVENT:

The primary outcome event was first time occurrence of HCC through to 31 Jan 2017 following commencement of antiviral therapy. We used the date of HCC diagnosis (i.e. date of the first cross-sectional image meeting HCC diagnostic criteria [17], or, if performed, the date of biopsy diagnostic

of HCC) as a surrogate for time of HCC occurrence. HCC diagnoses in this cohort will have been triggered either through (i) symptomatic onset of HCC, or (ii) six-monthly abdominal ultrasound screening (which, as per best practice guidelines [17], is offered to all patients diagnosed with cirrhosis in Scotland). We identified all new post-treatment diagnoses of HCC through the clinical database and medical chart review. All cases identified were cross-checked against instances of HCC registered in the Scottish Cancer database –which, at the time of analysis, provided complete individual-level data on cancer incidence up until 31 Dec 2014 – to ensure no HCC events were missed. For each identified case of HCC, we sought via medical chart review, information on the number of HCC nodules; and the maximum HCC nodule diameter at the time of HCC diagnosis; this aspect of the chart review was completed by the lead clinician at the clinic where the individual(s) in question attained SVR. We also collected data on the last abdominal ultrasound screening test for HCC through to 1 August 2016 for all individuals in the cohort.

PRIMARY EXPOSURE VARIABLE

The primary exposure variable was the type of treatment regimen received- specifically whether the regimen included interferon, or whether the regimen was interferon-free. We also explored an alternative definition, whether or not the course of therapy included a DAA.

DATA ON AND DEFINITIONS OF RELEVANT COVARIATES:

Data on a wide range of baseline covariates were included in this analysis. These were as follows: age; gender; ethnicity; Child-Turcotte-Pugh (CTP) score; platelet count; alphafetoprotein; diabetes, alcohol use history; smoking; HCV transmission route; genotype; previous treatment history and deprivation status and clinic location. CTP score assigns each individual into one of three levels of cirrhosis severity (the least severe being level A, and the most severe being level C), based on pre-treatment bilirubin, albumin, prothrombin time and the presence/absence of ascites and encephalopathy. For the bilirubin, albumin and prothrombin time components of this score, we used the most recent test carried out 0-90 days prior to treatment. Individuals who did not receive a prothrombin time test in this period were assumed to be CTP stage A if they did not have ascites or encephalopathy and had albumin level of $>3.5\text{g/dl}$, and bilirubin $<2\text{mg/dl}$ (applying to 21.1% of the cohort). Information on platelet count, and alphafetoprotein were similarly based on the most recent test carried out 0-90 days prior to starting treatment. Thrombocytopenia was defined as a platelet count of $<100\text{ per }10^9/\text{L}$. Clinic location was assessed in terms of whether the clinic attended was within or outside of the Greater Glasgow and Clyde (GGC) health board (the largest regional NHS board in Scotland with the greatest burden of diagnosed chronic HCV). Diabetes status referred to whether the patient had ever received a diagnosis of diabetes from a health professional. We defined a history of heavy alcohol use as consumption of more than 50 units of alcohol per week for six months or more, at any point in time. Previous treatment history refers to the number of treatment episodes

the patient had commenced prior to their eventual SVR. Data on mortality through to June 2016 were obtained via linkage to the Scottish mortality register, whilst mortality in the more recent period of June 2016-31 January 2017 was ascertained through the aforementioned medical chart review carried out by data entry staff in February-March 2017. Deprivation was measured through the Scottish Index of multiple deprivation (SIMD), which assigns a deprivation score to each address in Scotland. This SIMD score was obtained via an anonymised linkage to the Community Health Index database, which holds the address of each individual registered with a general practitioner in Scotland and maps that address to an SIMD score. For this analysis, we grouped the SIMD score into quintiles and compared outcomes in the two lower (i.e. two most deprived) quintiles to the three upper (i.e. most affluent) quintiles. All of these aforementioned data linkages were approved by the National Services Scotland Public Benefit Privacy Panel.

STATISTICAL ANALYSES

We adopted a survival analysis approach for this analysis. Follow-up time began at the treatment start date resulting in SVR, and ended at either: the date of HCC occurrence; the date of mortality, or 31 January 2017 (which ever came first). We calculated the unadjusted and adjusted association between treatment regimen and HCC occurrence using Cox regression. For the adjusted association between treatment regimen and HCC, we controlled for all co-factors associated either with the outcome (i.e. HCC occurrence) or with the primary exposure (i.e. treatment regimen). For this we defined “association” conservatively as that demonstrating a p-value <0.1 . We also fitted an interaction term between time-period (defined as before and after 24 weeks post-treatment completion) and HCC occurrence to assess the timing of HCC occurrence according to treatment regimen. Conformity to the proportional hazards assumption was assessed graphically and via the Schoenfeld residual test.

SENSITIVITY ANALYSES:

We carried out two one-way sensitivity analyses (SA). In SA-1 we additionally censored follow-up time at the date of last HCC screening attrition (if at all). The HCC screening attrition date was defined as date of the last ultrasound screening test plus 6 months, with 6 months referring to the recommended regularity of HCC screening for patients with cirrhosis[17]. In SA-2 we explored an alternative definition of treatment regimen; that being DAA-containing versus DAA-free.

RESULTS:

DERIVATION OF FINAL COHORT.

We identified 902 patients commencing treatment and attaining SVR between Jan 1997 and April 2016, who were not co infected with either HIV or hepatitis B virus. From this initial cohort, we excluded 43 patients with a date of HCC diagnosis prior to their treatment start date. We also excluded all patients diagnosed with HCC after the onset of therapy if suspicion of their HCC predated the antiviral therapy start date (N=2, both with suspicious focal lesions on pre-treatment ultrasound, confirmed on MRI as HCC post treatment initiation). Our final sample therefore comprised 857 patients.

DESCRIPTION OF COHORT AT BASELINE

Approximately a third (31.7%) of the cohort were treated with an IFN-free regimen, whilst the remainder received an IFN-containing regimen. The most common IFN-free regimen received was sofosbuvir+ledipasvir±ribavirin (58.8%) followed by sofosbuvir+daclatasvir (16.2% - see eTable 1). Most patients treated with IFN-containing therapy received either pegylated interferon±ribavirin (47.4%), or pegylated interferon±ribavirin+sofosbuvir (38.1%). Patients treated with IFN-free therapy were different in many respects to patients treated with IFN-containing therapy. Specifically, those treated with an IFN-free regimen were more likely to have/be: older; of white ethnicity, CTP- B/C; thrombocytopenic; non-genotype 3; failed HCV treatment at least twice in the past; been treated outside of GGC (see Table 1).

HCC OCCURRENCE DURING FOLLOW-UP:

The median duration of follow-up was 2.4 years overall, but varied markedly by treatment regimen (1.7 and 3.5 year for IFN-free and IFN-containing recipients, respectively). Over this follow-up period, 46 cases of HCC occurrence were identified. Of these, 34 and 12 were treated with an IFN-containing and IFN-free regimen, respectively. The crude rate of HCC occurrence was 1.45 events per 100 person years (95% CI: 1.09-1.94). However, there was variation in this crude rate by treatment regimen; the event rate was 1.26 per 100 person-years for individuals treated with IFN-containing therapy, versus 2.53 for individuals treated with IFN-free therapy (see Table 2 and eFigure.1). Most cases of HCC occurrence (61%) comprised a single nodule. The median diameter of the largest HCC nodule was 2.6cm. No significant differences in the number of nodules or the maximum nodule size, were observed with respect to IFN-free versus IFN-containing regimens (see Table 3 and eTable.2).

FACTORS ASSOCIATED WITH HCC OCCURRENCE.

In univariate analysis, individuals treated with an IFN-free regimen had a significantly higher risk of HCC occurrence relative to individuals treated with an IFN-containing regimen (HR: 2.48; 95% CI: 1.14-5.37) – see Table 4. Other factors associated (at p-value <0.1) with an increased risk of HCC occurrence in univariate analysis were: increasing age; CTP-B/C; thrombocytopenia; alphafetoprotein ≥ 10 ng/ml; failing HCV treatment at least twice in the past; and treatment outside of GGC

The higher risk associated with IFN-free regimens in univariate analyses was considerably attenuated after multivariate adjustment (aHR:1.15; 95% CI: 0.49-2.71)- see Table 5. The two biggest contributors to this attenuation were adjustment for pre-treatment platelet count and CTP score (see Figure.1). The association between treatment regimen and HCC occurrence was consistent across time period with no suggestion of clustering by time (see Figure 2). Factors that were significantly associated in multivariate analysis with HCC occurrence at p<0.05 were: (i) age 50-59years vs 40-49years (aHR:2.68; p=0.006); (ii) age 60+years vs 40-49 years (aHR:3.62;p=0.008); (iii) CTP-B/C Vs CTP-A (aHR:2.58; p=0.021); (iv) thrombocytopenia (aHR: 2.68; p=0.006); and (v) prior failure of 2+ courses of therapy (aHR: 2.52, p=0.041). No violations of the proportional hazards assumption were observed in either univariate or multivariate models.

SENSITIVITY ANALYSES:

In SA-1, more than half (55%) of the cohort were censored for HCC screening attrition (see eTable 3). The unadjusted association between regimen (IFN-free versus IFN-containing) and HCC was HR:2.82 (95% CI: 1.04-7.63). This association attenuated to HR: 1.28 (95% CI: 0.41-4.00) following full multivariate adjustment. Thus, the pattern of association between treatment regimen and HCC occurrence was similar between SA-1 and our basecase analysis (see eFigure.2). When defined in terms of DAA-containing versus DAA-free (SA2), treatment regimen was not associated with HCC occurrence, either at the univariate level (HR: 1.36; 95% CI: 0.66-2.79), or in multivariate analysis (aHR: 0.57; 95% CI: 0.24-1.40).

DISCUSSION

PRINCIPLE FINDINGS:

Recent studies from Europe have warned that the risk of HCC occurrence in cirrhotic individuals may be higher after attaining an IFN-free hepatitis C cure versus an IFN-containing cure. [6-8] Although this finding could have major implications for the treatment of HCV, the studies on which it was predicated did not carry out multivariate adjustment for confounding factors, and involved small sample sizes only. In the present study, our aim was to investigate the issue of HCC occurrence by treatment regimen more robustly using data from the Scottish clinical database – a large unselected nationwide cohort of individuals treated for chronic hepatitis C infection. Of 857 cirrhotic patients attaining SVR between 1997-2016, we did find, *prima facie*, a 2.5 fold higher risk of HCC occurrence among patients receiving an IFN-free regimen compared to an IFN-containing regimen (HR: 2.48; 95% CI: 1.14-5.37). Yet, as noted previously elsewhere [12,18], the baseline characteristics of individuals with an IFN-free cure were demonstrably different from those with an IFN-containing cure. Specifically, patients with an IFN-free cure were more likely to: be older; have a CTP score of B/C versus A; be thrombocytopenic; and be treatment experienced. A major finding from this study therefore, is that upon adjusting for these differences (in particular differences in CTP score and platelet count – see Figure.1), the elevated risk of HCC associated with IFN-free regimens was almost entirely attenuated (aHR:1.15; 95% CI: 0.49-2.71). This would tend to indicate that the higher risk of HCC occurrence among individuals receiving IFN-free therapy is a reflection of the shifting patient case mix, as opposed to the pharmacodynamics of IFN-free therapy or any other direct or indirect consequence of IFN-free therapy itself.

COHERENCE WITH PREVIOUS WORK:

The initial studies suggesting a higher risk of HCC occurrence following a IFN-free cure versus an IFN-containing cure [6-8] entailed small sample sizes and did not perform multivariate regression against a suitable control group. The present study is consistent with these initial data however, insofar as we too, before multivariate adjustment, found an increased risk of HCC occurrence among patients receiving IFN-free therapy. Yet, this study advances that initial work by reporting considerable attenuation in that “higher” risk after adjustment for relevant confounding factors. Our findings are also consistent with recent work by Cheung et al from England. [19] This study reported that, of 406 patients with decompensated cirrhosis treated with IFN-free therapies, HCC occurred in 4.2% of patients during the first six months from commencing treatment. Although this incidence, at first glance, is high (at least in respect to individuals receiving a IFN-containing cure[9,10]), it was nevertheless equivalent to occurrence seen in a matched control group comprising untreated patients at a comparable disease stage. Thus, similar to this present study, Cheung et al found no evidence for an elevated risk of HCC occurrence following IFN-free treatment after benchmarking against an

appropriate control group (albeit this study is likely to suffer from the same limitations around HCC surveillance as outlined for this study; see strength and limitations paragraph).

STRENGTHS AND LIMITATIONS:

A significant strength of this study is that it robustly addresses a very topical issue, of major importance to patients with HCV and the field of HCV treatment in general. A second strength is that our cohort comprises a majority (c.85%) of cured patients in Scotland. In contrast, previous studies examining this question [5-8] were confined to patients attending a smaller number of potentially select clinics and may not have been representative of the wider treated/cured population. This study has several limitations however. Firstly, although our study is one of the largest to-date to examine the risk of HCC occurrence according to IFN-free versus IFN-containing regimens, our sample size may nevertheless still be inadequate to detect a difference in the risk of HCC by regimen, if that difference was small. Secondly, whilst six-monthly abdominal ultrasound examinations were offered to all patients in this cohort, the uptake of this offer was suboptimal. SA-1 indicates that at least 55% of our cohort had missed a six monthly ultrasound exam at least once during follow-up. This poor compliance has been found in other settings too [20], however the issue did not affect our headline results – i.e. the pattern of association between regimen and HCC after including additional censoring for screening attrition was no different to our base-case result (see eFigure.2). Indeed, even though adherence to HCC surveillance is suboptimal, most HCC patients will present anyway with symptomatic disease within a relatively short timeframe if not identified through screening; as such one would not necessarily expect this limitation to cause appreciable bias. Another issue is that patients were not necessarily screened for HCC at time zero (i.e. at the point of starting antiviral therapy). Thus, we cannot be absolutely certain that the incident HCC cases identified in our cohort weren't already present at the time of starting antiviral therapy. However, we did exclude all cases of HCC that were diagnosed prior to antiviral therapy, and further excluded all cases diagnosed *after* antiviral therapy if suspicion of that HCC predated treatment onset. Fourthly, a diagnosis of liver cirrhosis was a key eligibility condition for this study. Over the time frame of this study, a cirrhosis diagnosis would typically have been made through a combination of: (i) liver biopsy; (ii) transient elastography; (iii) abdominal ultrasound; (iv) clinical examination and (v) routine liver function tests. However, a further limitation of this study is that we lacked data to describe the exact modality/combination of modalities used to make this diagnosis. Fifthly our study only examined the risk of HCC occurrence, and not of HCC *recurrence*. The null association noted here between an IFN-free cure and HCC occurrence, doesn't in itself rule out an association between an IFN-free cure and HCC recurrence. Although one recent study entailing controlled comparisons from three prospective French cohorts, has recently cast doubt on this association too. [21] Finally, inclusion in this study required a diagnosis of SVR, meaning that study participants must have survived the time interval between starting treatment and eligibility for SVR 12/SVR 24 assessment. Treatment responders who

developed HCC during treatment and died soon after would have been excluded from this study if they did not live long enough to demonstrate SVR; our methods therefore may have missed a small number of patients with rapidly progressive disease. Patients with HCC may be less likely to achieve an SVR [22], and examination of risk of HCC per regimen, independent of SVR would be an alternative approach. The manpower required to conduct casenote review of the large numbers of historic treatment failures, together with the small number of treatment failures with DAAs, made this approach impractical. In addition, assumed equivalence with IFN achieved SVR underpins the rationale and cost effectiveness for treatment with DAAs, making testing this assumption of vital importance.

CONCLUSIONS:

This study, based on data from a large and representative sample of cured hepatitis C patients in Scotland, suggests that the higher risk of HCC occurrence following receipt of IFN-free therapies reflects a change in patient case mix, as opposed to the direct or indirect consequences of IFN-free therapy per se. However, further data from other large cohorts should be sought to confirm these findings.

ACKNOWLEDGEMENTS: The authors would like to thank: Jacqueline Dickson; Marie Murray, Wendy Mitchell, Anne-Marie Sinclair, Elaine Cadzow, Joe Schofield, Susan Gilfillan, Johnathon Campbell, Sharon Davidson, Cathy Scott, and Shirley Cleary for their hard work in carrying out the medical chart review for the patients contributing to this study.

FIGURE LEGENDS

FIGURE 1: Association between interferon-free therapy (versus interferon-containing) and HCC occurrence, according to level of covariate adjustment. Partial adjustment refers to adjustment for: age, Child-Turcotte-Pugh score, thrombocytopenia, and number of prior treatment episodes. Full adjustment refers to adjustment for: age, gender, ethnicity, Child –Turcotte-Pugh score, thrombocytopenia, alphafetoprotein, genotype, number of prior treatment episodes, and clinic location

FIGURE 2: Fig.2: Association between interferon-free therapy (versus interferon-containing) and HCC occurrence, by time period. Partial adjustment refers to adjustment for: age, Child-Turcotte-Pugh score, thrombocytopenia, and number of prior treatment episodes. Full adjustment refers to adjustment for: age, gender, ethnicity, Child –Turcotte-Pugh score, thrombocytopenia, alphafetoprotein, genotype, number of prior treatment episodes, and clinic location

REFERENCES:

- [1] Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir” Clin Infect Dis. 2015;60:1829-1836.
- [2] Jacobson IM, Lawitz E, Kwo PY, Hezode C, Peng CY, Howe AYM, et al. Safety and efficacy of elbasvir/gazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017. In press
- [3] Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308: 2548-2593.
- [4] Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263-70.
- [5] Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016; in press.
- [6] Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol; 2016;65:727-733.
- [7] Cardoso H, Vale AM, Rodriguez S, Goncalves R; Albuquerque A; Pereira P, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol; 2016; 65:1070-71
- [8] Kozbial K, Moser S, Schwarzer R, Laferi H, Al-Zoairy R, Stattermayer AF, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-868.
- [9] Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54.
- [10] Van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaraso V, Fernandex-Rodriguez M, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017; 66:485-493
- [11] El-Serag ; Kanwal F; Richardson P; Kramer J. Risk of hepatocellular carcinoma after sustained viral response in veterans with hepatitis C virus infection. Hepatology; 2016;64:130-137.
- [12] Toyada H, Kumada T, Tada T. Changes in patient background may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology 2016;64:1818-1819.
- [13] McDonald SA, Hutchinson SJ, Innes HA, Allen S, Bramley P, Bhattacharyya D, et al. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically

infected with hepatitis C: examining the early impact of Scotland's hepatitis C action plan. *J Viral Hepat* 2014; 21:366-76.

[14] Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. *Hepatology* 2015; 62:355-64.

[15] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. *J Hepatol* 2014; 61:373-395.

[16] Yoshida EM, Sulkowski MS, Gane EJ, Herring RW, Ratzliff V, Ding X, et al. Concordance of sustained virological response 4, 12 and 24 weeks post-treatment with sofosbuvir-containing regimens for Hepatitis C. *Hepatology* 2015; 61:41-45.

[17] European Association for the study of the liver. EASL-EORTC Clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; 56:908-943

[18] Janjua NZ, Islam NB, Wong J, Yoshida EM, Ramji A, Samiji H, et al. Shift in disparities in hepatitis C treatment from interferon to DAA era: a population-based cohort study. *J Viral Hepat* 2017. In press.


[19] Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Multimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. *J Hepatol* 2016; 65:741-747.

[20] Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, El-Serag HB. Utilisation of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. *Ann Intern Med*. 2011;154:85-93.

[21] The ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. *J Hepatol*. 2016;65:734-740.

[22] Beste LA, Green PK, Berry K, Koqut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. *J Hepatol* 2017; in press.


Figure 1: Association between interferon-free therapy (versus interferon-containing) and HCC occurrence, according to level of covariate adjustment



* Partial adjustment refers to adjustment for: age, Child-Turcotte-Pugh score, thrombocytopenia, and number of prior treatment episodes

** Full adjustment refers to adjustment for: age, gender, ethnicity, Child –Turcotte-Pugh score, thrombocytopenia, alphafetoprotein, genotype, number of prior treatment episodes, and clinic location

Fig.2: Association between interferon-free therapy (versus interferon-containing) and HCC occurrence, by time period



* Partial adjustment refers to adjustment for: age, Child-Turcotte-Pugh score, thrombocytopenia, and number of prior treatment episodes

** Full adjustment refers to adjustment for: age, gender, ethnicity, Child-Turcotte-Pugh score, thrombocytopenia, alpha-fetoprotein, genotype, number of prior treatment episodes, and clinic location

Table 1: Characteristics of final cohort, according to treatment regimen received

Variable category	Variable		IFN-free regimen		TOTAL (N=857) Number (col% *)	p-value**	
			No (N=585)	Yes (N=272)			
			Number (col% *)	Number (col% *)			
Socio-demographic factors	Age category, years	<40	87 (14.9)	17 (6.3)	104 (12.1)	<0.001	
		40-49	268 (46.0)	105 (38.6)	374 (43.6)		
		50-59	179 (30.6)	102 (37.5)	281 (32.8)		
		60+	50 (8.6)	48 (17.7)	98 (11.4)		
	Age, mean		48.1 (8.1)	52.1 (8.6)	49.4 (8.5)	<0.001†	
	Gender	Female	134 (22.9)	78 (28.7)	212 (24.7)	0.068	
		Male	451 (77.1)	194 (71.3)	645 (75.3)		
	Ethnicity	White	530 (90.6)	261 (96.0)	791 (92.3)	0.006	
		Asian/other	55 (9.4)	11 (4.0)	66 (7.7)		
	Deprivation quintile of resident address	quintiles 1-2 (i.e. bottom 40%)	408 (70.7)	187 (69.5)	595 (70.3)	0.723	
quintils 3-5 (i.e. top 60%)		169 (29.3)	82 (30.5)	251 (29.7)			
Unknown		8 (-)	3 (-)	11 (-)			
Pre-treatment Liver disease markers	Child-Turcotte-Pugh score	A	420 (90.5)	133 (69.6)	553 (84.4)	<0.001	
		B/C	44 (9.5)	58 (30.4)	102 (15.6)		
		Unknown	121 (-)	81 (-)	202 (-)		
	Thrombocytopenia	No	415 (77.9)	153 (60.7)	568 (72.4)	<0.001	
		Yes	118 (22.1)	99 (39.3)	217 (27.6)		
		Unknown	52 (-)	20 (-)	72 (-)		
	Platelet count, 10 ⁹ /L, mean		152.3 (64.1)	131.2 (72.9)	145.6 (67.7)	<0.001‡	
	Alphafetoprotein category , ng/ml	<10	277 (78.0)	125 (72.7)	402 (76.3)	0.175	
		≥10	78 (22.0)	47 (27.3)	125 (23.7)		
		Unknown	230 (-)	100 (-)	330 (-)		
		Alphafetoprotein, ng/ml, mean		9.6 (18.1)	10.9 (18.6)		10.1 (18.3)
	Comorbidities/health behaviours	Diabetes present at treatment	No	515 (90.4)	250 (92.3)	765 (91.0)	0.369
			Yes	55 (9.7)	21 (7.8)	76 (9.0)	
Unknown			15 (-)	1 (-)	16 (-)		
History of heavy alcohol use at first clinic appointment		No	288 (57.5)	121 (52.8)	409 (56.0)	0.241	
		Yes	213 (42.5)	108 (47.2)	321 (44.0)		
		Unknown	84 (-)	43 (-)	127 (-)		
Current smoker at first clinic appointment		No	123 (28.3)	52 (25.5)	175 (27.4)	0.452	
		Yes	311 (71.7)	152 (74.5)	463 (72.6)		
		Unknown	151 (-)	68 (-)	219 (-)		
Risk group		IDU	351 (70.3)	163 (70.3)	514 (70.3)	0.982	
	non-IDU	148 (29.7)	69 (29.7)	217 (29.7)			
	Unknown	86 (-)	40 (-)	126 (-)			
Virology data	HCV genotype	3	375 (64.3)	73 (27.2)	446 (52.6)	<0.001	
		non-3	208 (35.7)	195 (72.8)	403 (47.4)		
		unknown	2 (-)	4 (-)	6 (-)		
Treatment data	Number of prior treatment episodes	0	424 (72.5)	130 (47.8)	554 (64.6)	<0.001	
		1	122 (20.9)	96 (35.3)	218 (25.4)		
		2+	39 (6.7)	46 (16.9)	85 (9.9)		
Geographical factors	Clinic location	Within Greater Glasgow and Clyde	409 (69.9)	162 (59.6)	571 (66.6)	0.003	
		Outwith Greater Glasgow and Clyde	176 (30.1)	110 (40.4)	286 (33.4)		

* The Col % excludes unknowns where an unknown category exists. For continuous variables the standard deviation is shown as column % is not applicable

N.B. p-values were generated via a Chi-squared test unless indicated otherwise. We excluded "unknown" categories from this test where an "unknown" category existed

† p-value generated via a t-test; ‡p-value generated via a Wilcoxon rank sum test.

* The Col % excludes unknowns where an unknown category exists. For continuous variables the standard deviation is shown as column % is not applicable

N.B. p-values were generated via a Chi-squared test unless indicated otherwise. We excluded "unknown" categories from this test where an "unknown" category existed

† p-value generated via a t-test; ‡ p-value generated via a Wilcoxon rank sum test.

Table 2: Description of follow-up (FU) data and outcome events, by treatment regimen received				
		IFN-free regimen		All regimens
		No	Yes	
Total persons		585	272	857
Total person years follow-up		2697	475	3173
Average person years per patient	Median	3.5	1.7	2.4
	Mean	4.6	1.7	3.7
Number of outcome events (i.e. HCC occurrences)	Total number of events	34	12	46
	no occurring <24 weeks post-treatment	6	5	11
	no occurring 24+weeks post-treatment	28	7	35
Time to outcome event, person years	mean time to event	3.4	1.0	2.8
	median time to event	2.5	0.9	2.0
	minimum time to event	0.3	0.47	0.3
	maximum time to event	8.5	2.0	8.5
Crude outcome rate, per 100 person years (95% CI)		1.3 (0.9-1.8)	2.5 (1.4-4.4)	1.4 (1.1-1.9)

		IFN-free regimen		All	P-value
		No	Yes		
Total number of HCC nodules, n(col%)	1	17 (56.7)	8 (72.7)	25 (61.0)	0.54*
	2	8 (26.7)	1 (9.1)	9 (22.0)	
	≥3	5(16.7)	2 (18.2)	7 (17.1)	
Maximum HCC nodule diameter, cm	Mean	3.3	2.6	3.1	0.61†
	Median	2.7	2.1	2.6	
N.B. data for number of nodules and nodule size missing in 5 cases					
* p-value generated using the Fisher's exact test; † p-value generated using the Wilcoxon rank sum test					


Table 4: Factors associated with occurrence of HCC: univariate analysis

Variable category	Variable		Number (col%)	HCC occurrence	Univariate hazard ratio (95% CI)	p-value*
Primary exposure variable	IFN-free regimen	No	585 (68.3)	34	REF (1.00)	\
		Yes	272 (31.7)	12	2.48 (1.14-5.37)	0.021
Socio-demographic factors	Age category, years	<40	104 (12.1)	1	0.20 (0.03-1.56)	0.125
		40-49	374 (43.6)	13	REF (1.00)	\
		50-59	281 (32.8)	24	2.75 (1.40-5.41)	0.003
		60+	98 (11.4)	8	3.31 (1.37-8.02)	0.008
	Gender	Female	212 (24.7)	8	REF (1.00)	\
		Male	645 (75.3)	38	1.59 (0.74-3.41)	0.232
	Ethnicity	White	791 (92.3)	43	REF (1.00)	\
		Asian/other	66 (7.7)	3	0.68 (0.21-2.19)	0.515
	Deprivation quintile	quintiles 1-2 (i.e. bottom 40%)	595 (70.3)	29	REF (1.00)	\
		quintils 3-5 (i.e. top 60%)	251 (29.7)	17	1.16 (0.63-2.12)	0.631
		Unknown	11 (-)	0	\	\
Pre-treatment Liver disease markers	Child-Turcotte-Pugh score	A	553 (84.4)	20	REF (1.00)	
		B/C	102 (11.9)	14	5.24 (2.63-10.46)	<0.001
		Unknown	202 (-)	12	1.55 (0.76-3.18)	0.231
	Thrombocytopenia	No	568 (66.3)	18	REF (1.00)	\
		Yes	217 (25.3)	24	3.96 (2.14-7.30)	<0.001
		Unknown	72 (-)	4	1.26 (0.42-3.74)	0.677
	Alphafetoprotein category , ng/ml	<10	402 (76.3)	19	REF (1.00)	
		≥10	125 (14.6)	13	2.26 (1.11-4.58)	0.024
		Unknown	330 (-)	14	0.77 (0.39-1.54)	0.462
Comorbidities/health behaviours	Diabetes present at treatment	No	765 (89.3)	39	REF (1.00)	\
		Yes	76 (8.9)	7	1.51 (0.67-3.39)	0.315
		Unknown	16 (-)	0	\	\
	History of heavy alcohol use at first clinic appointment	No	409 (56.0)	17	REF (1.00)	\
		Yes	321 (44.0)	20	1.47 (0.77-2.81)	0.244
		Unknown	127 (-)	9	1.71 (0.76-3.83)	0.196
	Current smoker at first clinic appointment	No	175 (27.4)	9	REF (1.00)	\
		Yes	463 (72.6)	23	1.05 (0.49-2.28)	0.897
		Unknown	219 (-)	14	1.30 (0.56-3.01)	0.535
	Risk group	IDU	514 (70.3)	23	REF (1.00)	\
		non-IDU	217 (29.7)	15	1.37 (0.72-2.64)	0.340
		Unknown	126 (-)	8	1.49 (0.67-3.34)	0.329
Virology data	HCV genotype	3	446 (52.6)	28	REF (1.00)	\
		non-3	403 (47.4)	17	0.88 (0.48-1.61)	0.677
		unknown	6 (-)	1	2.37 (0.32-17.54)	0.397
Treatment data	Number of prior treatment episodes	0	554 (64.6)	28	REF (1.00)	\
		1	218 (25.4)	10	1.44 (0.69-3.01)	0.336
		2+	85 (9.9)	8	3.52 (1.56-7.95)	0.002
Geographical factors	Clinic location	Within Greater Glasgow and Clyde	571 (66.6)	21	REF (1.00)	
		Outwith Greater Glasgow and Clyde	286 (33.4)	25	2.01 (1.12-3.61)	0.020
* p-value generated via the wald test						

Table 5: Factors associated with occurrence of HCC: multivariate analysis

Variable category	Variable		Adjusted hazard ratio (95% CI)	p-value*
Primary exposure variable	IFN-free regimen	No	REF (1.00)	\
		Yes	1.15 (0.49-2.71)	0.744
Socio-demographic factors	Age category, years	<40	0.18 (0.02-1.36)	0.096
		40-49	REF (1.00)	\
		50-59	2.68 (1.33-5.37)	0.006
		60+	3.62 (1.41-9.30)	0.008
	Gender	Female	REF (1.00)	\
		Male	1.71 (0.78-3.74)	0.183
	Ethnicity	White	REF (1.00)	\
Asian/other		0.33 (0.09-1.18)	0.089	
Pre-treatment Liver disease markers	Child-Turcotte -Pugh score	A	REF (1.00)	\
		B/C	2.58 (1.16-5.76)	0.021
		Unknown	1.45 (0.63-3.30)	0.382
	Thrombocytopenia	No	REF (1.00)	\
		Yes	2.68 (1.32-5.45)	0.006
		Unknown	1.42 (0.40-4.96)	0.586
	Alphafetoprotein category , ng/ml	<10	REF (1.00)	\
≥10		1.59 (0.74-3.39)	0.289	
Unknown		0.90 (0.42-1.90)	0.775	
Virology data	HCV genotype	3	REF (1.00)	
		non-3	0.65 (0.33-1.26)	0.202
		unknown	3.90 (0.47-32.07)	0.205
Treatment data	Number of prior treatment episodes	0	REF (1.00)	\
		1	1.39 (0.64-3.02)	0.407
		2+	2.52 (1.04-6.13)	0.041
Geographical factors	Clinic location	Within Greater Glasgow and Clyde	REF (1.00)	\
		Outwith Greater Glasgow and Clyde	1.61 (0.88-2.96)	0.126
* p-value generated via the wald test				

The risk of hepatocellular carcinoma for cirrhotic patients with a hepatitis C sustained viral response, by treatment regimen



HIGHLIGHTS:

- Crude risk of HCC higher for IFN-free recipients than IFN-containing recipients
- IFN-free and IFN-containing recipients differ with respect to confounding factors
- Association between IFN-free therapy and HCC disappears after adjusting for baseline confounders
- At HCC diagnosis, no differences in nodule size or nodule number were apparent by regimen (albeit numbers were small).